India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

About 71% of U.S. adults are either overweight or obese, according to the Centers for Disease Control. That makes it easy to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Department of Mathematics, School of Science, Research Center for Econophysics, East China University of Science and Technology, Shanghai 200237, P. R. China ...

Frankly: Yes. The people who go to fine dining restaurants are, by definition, rich. They can all afford Mounjaro and Ozempic. And most are a little concerned about their weight. They have already ...

Omada Health is launching new AI tools for nutrition care after filing its S-1 to go public.

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.